Published: 15 March 2022
Author(s): Yasemin Cag, Hakan Erdem, Mehmet Gunduz, Suheyla Komur, Handan Ankarali, Serap Ural, Meltem Tasbakan, Pierre Tattevin, Anil Tombak, Derya Ozturk-Engin, Ayse Sagmak Tartar, Ayse Batirel, Recep Tekin, Fazilet Duygu, Hulya Caskurlu, Behice Kurtaran, Bulent Durdu, Demet Haciseyitoglu, Jordi Rello, ID-IRI Mucormycosis Study Group
Issue: June 2022
Section: Original article

Mucormycosis is an aggressive mold infection that mostly attacks patients with certain underlying conditions such as diabetes, hematological malignancies, neutropenia, major solid organ transplantation, or hematopoietic stem cell transplantation [1,2]. Given the increased prevalence of predisposing conditions in the modern era including Coronavirus disease 2019 (COVID-19) [3,4], the incidence of mucormycosis has increased as well [5–8]. Despite the advances in modern medicine, rhino-orbito-cerebral mucormycosis (ROCM) still has excessively high mortality rates.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.